Search

Your search keyword '"Tilsted, Hans-Henrik"' showing total 55 results

Search Constraints

Start Over You searched for: Author "Tilsted, Hans-Henrik" Remove constraint Author: "Tilsted, Hans-Henrik" Publisher elsevier bv Remove constraint Publisher: elsevier bv
55 results on '"Tilsted, Hans-Henrik"'

Search Results

1. International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial – rationale and design

2. Comparison of Effect of Ischemic Postconditioning on Cardiovascular Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention With Versus Without Thrombectomy

3. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study

4. Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction

5. Electrocardiogram to predict reperfusion success in late presenters with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

6. Sub-acute cardiac magnetic resonance to predict irreversible reduction in left ventricular ejection fraction after ST-segment elevation myocardial infarction: A DANAMI-3 sub-study

8. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial

9. Bleeding Events After ST-segment Elevation Myocardial Infarction in Patients Randomized to an All-comer Clinical Trial Compared With Unselected Patients

10. Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study

11. Relation of Bleeding Events to Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention (a DANAMI-3 Substudy)

12. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial

13. Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents

14. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial

15. Influence of multivessel disease with or without additional revascularization on mortality in patients with ST-segment elevation myocardial infarction

16. The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: Ischemic postconditioning or deferred stent implantation versus conventional primary angioplasty and complete revascularization versus treatment of culprit lesion only

17. Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial

19. Long-Term Outcome of Sirolimus-Eluting and Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (A Danish Organization for Randomized Trials on Clinical Outcome III Substudy)

20. TCT-641 Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease: SORT OUT IV 5-year

21. TCT-643 Very Late Stent Thrombosis after Revascularization with Biolimus-Eluting Biodegradable Polymer-Coated Nobori Stent versus Durable Polymer-Coated Sirolimus-Eluting Stents from the SORT OUT V Trial

23. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial

24. VERY LATE STENT THROMBOSIS AFTER REVASCULARIZATION WITH EVEROLIMUS- AND SIROLIMUS-ELUTING STENTS FROM THE SORT OUT IV TRIAL

25. LONG-TERM CLINICAL OUTCOMES OF EVEROLIMUS-ELUTING STENTS VERSUS SIROLIMUS-ELUTING STENTS IN PATIENTS WITH CORONARY ARTERY DISEASE: SORT OUT IV 4-YEAR

26. TCT-194 5-Year Outcome Of Zotarolimus-Eluting Versus Sirolimus-Eluting Coronary Stent Implantation In Patients With And Without Diabetes Mellitus

27. TCT-12 Short Versus Long-Term Clinical Outcomes In A Randomised Comparison Of Zotarolimus- and Sirolimus-Eluting Coronary Stents

28. TCT-598 Mechanisms of Incomplete Stent Apposition After Implantation of Drug-eluting Stents in patients with ST-segment Elevation Myocardial Infarction

29. Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction

30. LONG–TERM OUTCOME AFTER REVASCULARIZATION WITH EVEROLIMUS– AND SIROLIMUS–ELUTING STENTS IN PATIENTS WITH RENAL INSUFFICIENCY: FROM THE SORT OUT IV TRIAL

31. RISK FOR PERSISTENT RENAL DYSFUNCTION IN PATIENTS WITH CONTRAST–INDUCED NEPHROPATHY AFTER PRIMARY PCI

33. VERY LATE STENT THROMBOSIS AFTER REVASCULARIZATION WITH EVEROLIMUS AND SIROLIMUS–ELUTING STENTS: FROM THE SORT OUT IV TRIAL

34. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial

35. Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the SORT OUT IV Trial)

36. TCT-55 Major Adverse Cardiac Events Associated With Discontinuation Of Clopidogrel Treatment Within The First Year After Coronary Stent Implantation In Western Denmark

37. TCT-355 Coronary Stents In Patients With Diabetes Mellitus: The Diabetes And Drug-Eluting Stent (DiabeDES IV) Randomized Angiography Trial

38. TCT-347 Clinical Outcome Of Biolimus-Eluting Versus Sirolimus-Eluting Coronary Stent Implantation In Patients With And Without Diabetes Mellitus: A SORT OUT V Substudy

39. 2-Year Patient-Related Versus Stent-Related Outcomes

40. 3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents

41. IMPACT OF LESION LENGTH ON OUTCOMES AFTER REVASCULARIZATION WITH EVEROLIMUS AND SIROLIMUS ELUTING STENTS. A SUBSTUDY OF THE SORT OUT IV TRIAL

43. Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction

44. DEFINITE AND PROBABLE STENT THROMBOSIS AFTER REVASCULARIZATION WITH EVEROLIMUS- AND SIROLIMUS-ELUTING STENTS. FROM THE SORT OUT IV TRIAL

46. OUTCOMES AFTER REVASCULARIZATION WITH EVEROLIMUS AND SIROLIMUS ELUTING STENTS IN PATIENTS WITH SMALL AND LARGE CORONARY ARTERIES. A SUBSTUDY OF THE SORT OUT IV TRIAL

47. Outcome of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (a SORT OUT III Substudy)

48. Comparison of Outcomes of Patients ≥80 Years of Age Having Percutaneous Coronary Intervention According to Presentation (Stable vs Unstable Angina Pectoris/Non–ST-Segment Elevation Myocardial Infarction vs ST-Segment Elevation Myocardial Infarction)

50. Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction

Catalog

Books, media, physical & digital resources